Skip to main content

Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4.

Publication ,  Journal Article
Age-Related Eye Disease Study 2 (AREDS2) Research Group, ; Chew, EY; SanGiovanni, JP; Ferris, FL; Wong, WT; Agron, E; Clemons, TE; Sperduto, R ...
Published in: JAMA Ophthalmol
July 2013

IMPORTANCE: Age-related cataract is a leading cause of visual impairment in the United States. The prevalence of age-related cataract is increasing, with an estimated 30.1 million Americans likely to be affected by 2020. OBJECTIVE: To determine whether daily oral supplementation with lutein/zeaxanthin affects the risk for cataract surgery. DESIGN, SETTING, AND PATIENTS: The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, double-masked clinical trial, enrolled 4203 participants, aged 50 to 85 years, at risk for progression to advanced age-related macular degeneration. INTERVENTIONS: Participants were randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated fatty acids, 1 g; or a combination to evaluate the effects on the primary outcome of progression to advanced age-related macular degeneration. MAIN OUTCOMES AND MEASURES: Cataract surgery was documented at annual study examination with the presence of pseudophakia or aphakia, or reported during telephone calls at 6-month intervals between study visits. Annual best-corrected visual acuity testing was performed. A secondary outcome of AREDS2 was to evaluate the effects of lutein/zeaxanthin on the subsequent need for cataract surgery. RESULTS: A total of 3159 AREDS2 participants were phakic in at least 1 eye and 1389 of 6027 study eyes underwent cataract surgery during the study, with median follow-up of 4.7 years. The 5-year probability of progression to cataract surgery in the no lutein/zeaxanthin group was 24%. For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios for progression to cataract surgery was 0.96 (95% CI, 0.84-1.10; P = .54). For participants in the lowest quintile of dietary intake of lutein/zeaxanthin, the hazard ratio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to cataract surgery was 0.68 (95% CI, 0.48-0.96; P = .03). The hazard ratio for 3 or more lines of vision loss was 1.03 (95% CI, 0.93-1.13; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin). CONCLUSIONS AND RELEVANCE: Daily supplementation with lutein/zeaxanthin had no statistically significant overall effect on rates of cataract surgery or vision loss. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00345176.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

JAMA Ophthalmol

DOI

EISSN

2168-6173

Publication Date

July 2013

Volume

131

Issue

7

Start / End Page

843 / 850

Location

United States

Related Subject Headings

  • Zeaxanthins
  • Xanthophylls
  • Visual Acuity
  • Vision Disorders
  • Male
  • Lutein
  • Humans
  • Female
  • Fatty Acids, Omega-3
  • Drug Therapy, Combination
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Age-Related Eye Disease Study 2 (AREDS2) Research Group, ., Chew, E. Y., SanGiovanni, J. P., Ferris, F. L., Wong, W. T., Agron, E., … Bernstein, P. (2013). Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmol, 131(7), 843–850. https://doi.org/10.1001/jamaophthalmol.2013.4412
Age-Related Eye Disease Study 2 (AREDS2) Research Group, Paul, Emily Y. Chew, John Paul SanGiovanni, Frederick L. Ferris, Wai T. Wong, Elvira Agron, Traci E. Clemons, et al. “Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4.JAMA Ophthalmol 131, no. 7 (July 2013): 843–50. https://doi.org/10.1001/jamaophthalmol.2013.4412.
Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, SanGiovanni JP, Ferris FL, Wong WT, Agron E, et al. Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmol. 2013 Jul;131(7):843–50.
Age-Related Eye Disease Study 2 (AREDS2) Research Group, Paul, et al. “Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4.JAMA Ophthalmol, vol. 131, no. 7, July 2013, pp. 843–50. Pubmed, doi:10.1001/jamaophthalmol.2013.4412.
Age-Related Eye Disease Study 2 (AREDS2) Research Group, Chew EY, SanGiovanni JP, Ferris FL, Wong WT, Agron E, Clemons TE, Sperduto R, Danis R, Chandra SR, Blodi BA, Domalpally A, Elman MJ, Antoszyk AN, Ruby AJ, Orth D, Bressler SB, Fish GE, Hubbard GB, Klein ML, Friberg TR, Rosenfeld PJ, Toth CA, Bernstein P. Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmol. 2013 Jul;131(7):843–850.

Published In

JAMA Ophthalmol

DOI

EISSN

2168-6173

Publication Date

July 2013

Volume

131

Issue

7

Start / End Page

843 / 850

Location

United States

Related Subject Headings

  • Zeaxanthins
  • Xanthophylls
  • Visual Acuity
  • Vision Disorders
  • Male
  • Lutein
  • Humans
  • Female
  • Fatty Acids, Omega-3
  • Drug Therapy, Combination